文献速递消化系统肿瘤

英国生物样本库中胰腺导管腺癌临床风险预测模型的开发与内部验证

Development and internal validation of a clinical risk prediction model for pancreatic ductal adenocarcinoma in the UK Biobank.
PubMed 文献 · Eur J Cancer · 2026-04-28

基于英国生物样本库365,326名40-69岁成人前瞻性队列,开发胰腺导管腺癌风险预测模型,5年内发生314例PDAC。模型纳入年龄、吸烟、饮酒、胰腺炎及血液指标,5年校准良好(O:E=0.994),时间依赖AUC为0.741,内部五折交叉验证稳定。

要点

  • 模型仅用常规临床与实验室变量,5年区分度AUC 0.741,校准良好。
  • 预测因子包括年龄、吸烟、饮酒、胰腺炎及肝酶、HDL、HbA1c等血检异常。
  • 可用于基层风险分层,但临床实施前需独立外部队列验证。

核心结论

  • 利用常规可获临床与实验室数据构建的PDAC风险预测模型校准良好且具有区分度,为基层风险分层提供可操作框架,但需外部验证后方可临床实施。

研究设计与样本

  • 基于英国生物样本库前瞻性队列,纳入2006-2010年招募的40-69岁成人365,326名,通过癌症登记、住院及死亡记录识别 incident PDAC。
  • 采用Cox比例风险模型后退法筛选预测因子,评估5年模型性能,内部验证采用五折交叉验证。

主要发现

  • 5年内发生314例PDAC。
  • 预测因子包括年龄、吸烟、饮酒、胰腺炎、丙氨酸/天冬氨酸氨基转移酶、高密度脂蛋白胆固醇、糖化血红蛋白A1c等血液检测异常。
  • 校准观察与预期比值0.994(95%CI 0.890-1.111),时间依赖ROC曲线下面积0.741。
  • 内部五折交叉验证证实性能稳定。

关键数值与推荐

  • 校准指标:O:E比值0.994(95%CI 0.890-1.111);integrated calibration index=2.402×10⁻⁵;E50=1.928×10⁻⁵;E90=3.283×10⁻⁵。
  • 区分度:时间依赖AUC 0.741。

临床怎么用

  • 在基层医疗中可利用常规可获的临床与实验室变量进行PDAC风险分层,识别高风险个体以考虑靶向筛查。
  • 模型包含可改变因素(如吸烟、饮酒),可支持风险干预。

局限性

  • 仅在英国生物样本库内进行内部验证,临床实施前需在独立队列中进行外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers. Earlier identification through improved risk prediction modelling represents a promising strategy for improving PDAC outcomes. We developed a PDAC risk prediction model using routinely available clinical risk factors, including modifiable factors, to enable targeted screening. METHODS: Data from the UK Biobank, a prospective cohort of adults aged 40-69 years recruited between 2006 and 2010, were used to develop a PDAC risk prediction model. Incident PDAC was identified through linkage to cancer registries, hospital admissions, and death records. Candidate predictors included demographic, lifestyle, clinical, and laboratory variables routinely available in primary care. Time-to-PDAC was analyzed using Cox proportional hazards models with backward selection. Model performance at 5 years was evaluated calibration and discrimination, with internal validation via 5-fold cross-validation. RESULTS: Among 365,326 participants, 314 incident PDAC cases occurred within 5 years. Predictors included age, cigarette smoking, alcohol intake, pancreatitis, blood test alterations (alanine/aspartate aminotransferase, high-density cholesterol, glycated hemoglobin A1c). The model showed good calibration (observed-to-expected ratio was 0.994 [95% CI 0.890-1.111]; integrated calibration index = 2.402 × 10⁻⁵; E50 = 1.928 × 10⁻⁵; E90 = 3.283 × 10⁻⁵) and discrimination (time‑dependent area under the receiver operating characteristic curve 0.741). Internal 5-fold cross-validation confirmed stable performance. CONCLUSION: We developed a well-calibrated and discriminative PDAC risk prediction model using routinely available clinical and laboratory data. This models offers an actionable framework for risk stratification in primary care settings, though external validation in independent cohorts is warranted before clinical implementation.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Rassy E, Delaloge S, Truong T, et al. Development and internal validation of a clinical risk prediction model for pancreatic ductal adenocarcinoma in the UK Biobank. Eur J Cancer. 2026. PMID: 42068760. doi:10.1016/j.ejca.2026.116767

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。